Nanobiotix S.A. ADR
Nanobiotix S.A. ADR is a biotechnology company focused on developing nanomedicine-based approaches for cancer treatment. The company’s current activities center on its proprietary physics-based technology platform, which is designed to enhance the effect of radiotherapy by targeting tumor cells more precisely. Its lead therapeutic candidate is being developed for use across several oncology settings, including solid tumors and other difficult-to-treat cancers. Nanobiotix serves the healthcare and life sciences market through research, clinical development, and potential commercialization of advanced cancer therapies, with a business model built around product candidates that integrate with existing treatment protocols. Headquartered in Paris, France, Nanobiotix operates as a clinical-stage company with a focus on oncology innovation and translational medical science.
$21.30
-$0.93 (-4.18%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-36.49% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 355.3%, still solid. Margins contracted 625.6pp, which offsets some of the top-line progress.
Negative free cash flow of -€34M. The business is consuming cash, not generating it. Operating margin contracted 625.6pp YoY, cost discipline may be slipping.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€30M
▲ +355.3% YoY
Net Income (TTM)
-€24M
▲ +64.8% YoY
Op. Margin
-36.49%
▼ -625.6pp YoY
ROIC
-11.69%
▲ +94.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€34M
▼ -66.5% YoY
Op. Cash Flow (TTM)
-€33M
▼ -70.9% YoY
Net Debt
€43M
Cash & Equiv.
€53M
Continue Research
Is Nanobiotix S.A. ADR (NBTX) overvalued?
Nanobiotix S.A. ADR (NBTX)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Nanobiotix S.A. ADR scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is Nanobiotix S.A. ADR a high-quality business?+
Nanobiotix S.A. ADR scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -36.5% operating margin and a -11.7% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Nanobiotix S.A. ADR a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh NBTX's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Biotechnology
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.